Brief: Acrivon Therapeutics Cash Runway Guidance Remains Unchanged From Latest 10-Q
08/12/2023 21:26
Dec 9 (Reuters) - Acrivon Therapeutics Inc ACRV.O :
* ACRIVON THERAPEUTICS INC - ON DEC 4, ENTERED INTO THIRD
AMENDMENT TO ONCOSIGNATURE DIAGNOSTIC AGREEMENT WITH AKOYA
BIOSCIENCES
* ACRIVON THERAPEUTICS- AMENDMENT ADDRESSES EXPANDED SCOPE
OF
WORK, INCREASES TOTAL DEVELOPMENT MILESTONE PAYMENTS TO AKOYA TO
AGGREGATE OF $17.3 MILLION
* ACRIVON THERAPEUTICS - CASH RUNWAY GUIDANCE REMAINS
UNCHANGED
FROM LATEST 10-Q FILED NOVEMBER 9, 2023
((Reuters.Briefs@thomsonreuters.com))
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks